外泌体在特发性肺纤维化中的研究进展
Research Progress of Exosomes in Idiopathic Pulmonary Fibrosis
DOI: 10.12677/acm.2025.1561922, PDF,   
作者: 惠娟娟:延安大学医学院,陕西 延安;常小红*:延安大学附属医院呼吸与危重症医学科,陕西 延安
关键词: 外泌体特发性肺纤维化研究进展Exosomes Idiopathic Pulmonary Fibrosis Research Progress
摘要: 特发性肺纤维化是一种慢性、进行性、纤维化性间质性肺炎,组织学和(或)胸部高分辨率CT特征性表现为普通型间质性肺炎,病因不清,好发于中老年男性人群,表现为纤维化重构和肺泡破坏。液体活检作为一种新型无创检测手段,其中外泌体作为一种通过递送特定细胞类型产生的功能性核酸和蛋白质来介导细胞间通讯,凭借其操作简便、患者耐受性高及可动态监测等优势,逐渐在肺纤维化及肿瘤方面的诊疗做出重要贡献。近些年来随着诊疗水平的提升,以及人们就诊意愿的提高,特发性肺纤维化被越来越多地诊断出来。但对于特发性肺纤维化的病因、发生发展、治疗等方面仍是难点,因此提高对肺纤维化的认识以及标准的治疗十分重要。本文就外泌体在肺纤维化病因、发生发展、诊断、治疗等方面的研究进展进行综述。
Abstract: Idiopathic pulmonary fibrosis is a chronic, progressive, fibrotic interstitial pneumonia. The histological and/or high-resolution chest CT characteristic manifestations are common interstitial pneumonia. The cause is unclear. It is more common in middle-aged and elderly men, presenting with fibrotic remodeling and alveolar destruction. Liquid biopsy, as a new type of non-invasive detection method, among which exosomes, as a means of mediating intercellular communication by delivering functional nucleic acids and proteins produced by specific cell types, have gradually made important contributions in the diagnosis and treatment of pulmonary fibrosis and tumors due to their advantages such as simple operation, high patient tolerance and dynamic monitoring. In recent years, with the improvement of diagnosis and treatment levels and the increase in people’s willingness to seek medical treatment, idiopathic pulmonary fibrosis has been diagnosed more and more. However, the etiology, occurrence and development, and treatment of idiopathic pulmonary fibrosis remain difficult points. Therefore, it is very important to enhance the understanding of pulmonary fibrosis and the standard treatment. This article reviews the progress of research on exosomes in the etiology, occurrence and development, diagnosis and treatment of pulmonary fibrosis.
文章引用:惠娟娟, 常小红. 外泌体在特发性肺纤维化中的研究进展[J]. 临床医学进展, 2025, 15(6): 1840-1845. https://doi.org/10.12677/acm.2025.1561922

参考文献

[1] 中华医学会呼吸病学分会间质性肺疾病学组. 特发性肺纤维化诊断和治疗中国专家共识[J]. 中华结核和呼吸杂志, 2016, 39(6): 427-432.
[2] 勃文. 国内首个特发性肺纤维化流行病学研究启动[N]. 中国医药报, 2018-01-10(04).
[3] 王小华, 段军. 特发性肺纤维化病因学的新进展[J]. 医学综述, 2014, 20(3): 414-416.
[4] Anel, A., Gallego-Lleyda, A., de Miguel, D., Naval, J. and Martínez-Lostao, L. (2019) Role of Exosomes in the Regulation of T-Cell Mediated Immune Responses and in Autoimmune Disease. Cells, 8, Article No. 154. [Google Scholar] [CrossRef] [PubMed]
[5] 叶灏鑫, 王晓旭, 李明霏, 等. 外泌体与肺纤维化研究进展[J]. 中国生物工程杂志, 2024, 44(4): 67-75.
[6] Xu, R., Rai, A., Chen, M., Suwakulsiri, W., Greening, D.W. and Simpson, R.J. (2018) Extracellular Vesicles in Cancer—Implications for Future Improvements in Cancer Care. Nature Reviews Clinical Oncology, 15, 617-638. [Google Scholar] [CrossRef] [PubMed]
[7] Popowski, K., Lutz, H., Hu, S., George, A., Dinh, P. and Cheng, K. (2020) Exosome Therapeutics for Lung Regenerative Medicine. Journal of Extracellular Vesicles, 9, Article ID: 1785161. [Google Scholar] [CrossRef] [PubMed]
[8] Kalluri, R. and LeBleu, V.S. (2020) The Biology, Function, and Biomedical Applications of Exosomes. Science, 367, eaau6977. [Google Scholar] [CrossRef] [PubMed]
[9] Tai, Y., Chen, K., Hsieh, J. and Shen, T. (2018) Exosomes in Cancer Development and Clinical Applications. Cancer Science, 109, 2364-2374. [Google Scholar] [CrossRef] [PubMed]
[10] Puglisi, S., Torrisi, S., Giuliano, R., Vindigni, V. and Vancheri, C. (2016) What We Know about the Pathogenesis of Idiopathic Pulmonary Fibrosis. Seminars in Respiratory and Critical Care Medicine, 37, 358-367. [Google Scholar] [CrossRef] [PubMed]
[11] Zhu, L., Chen, Y., Chen, M. and Wang, W. (2021) Mechanism of miR-204-5p in Exosomes Derived from Bronchoalveolar Lavage Fluid on the Progression of Pulmonary Fibrosis via AP1S2. Annals of Translational Medicine, 9, Article No. 1068. [Google Scholar] [CrossRef] [PubMed]
[12] 黄元, 管艳云, 蔡欣蕊, 等. 特发性肺纤维化发病机制的研究进展[J]. 中国医刊, 2024, 59(10): 1054-1059.
[13] Ibrahim, A., Ibrahim, A. and Parimon, T. (2021) Diagnostic and Therapeutic Applications of Extracellular Vesicles in Interstitial Lung Diseases. Diagnostics, 11, Article No. 87. [Google Scholar] [CrossRef] [PubMed]
[14] Yang, Y., Liu, Y., Chai, Y., Liu, K., Hu, W., Zhao, K., et al. (2022) Exosomes in Pathogenesis, Diagnosis, and Treatment of Pulmonary Fibrosis. Frontiers in Pharmacology, 13, Article ID: 927653.
[15] Njock, M., Guiot, J., Henket, M.A., Nivelles, O., Thiry, M., Dequiedt, F., et al. (2018) Sputum Exosomes: Promising Biomarkers for Idiopathic Pulmonary Fibrosis. Thorax, 74, 309-312. [Google Scholar] [CrossRef] [PubMed]
[16] Elliot, S., Catanuto, P., Pereira-simon, S., Xia, X., Shahzeidi, S., Roberts, E., et al. (2022) Urine-Derived Exosomes from Individuals with IPF Carry Pro-Fibrotic Cargo. eLife, 11, e79543. [Google Scholar] [CrossRef] [PubMed]
[17] Liu, Q., Bi, Y., Song, S., Zhu, K., Qiao, X., Wang, H., et al. (2023) Exosomal miR-17-5p from Human Embryonic Stem Cells Prevents Pulmonary Fibrosis by Targeting Thrombospondin-2. Stem Cell Research & Therapy, 14, Article No. 234. [Google Scholar] [CrossRef] [PubMed]
[18] Kadota, T., Fujita, Y., Araya, J., Watanabe, N., Fujimoto, S., Kawamoto, H., et al. (2021) Human Bronchial Epithelial Cell‐Derived Extracellular Vesicle Therapy for Pulmonary Fibrosis via Inhibition of TGF-β-WNT Crosstalk. Journal of Extracellular Vesicles, 10, e12124. [Google Scholar] [CrossRef] [PubMed]
[19] Guiot, J., Cambier, M., Boeckx, A., Henket, M., Nivelles, O., Gester, F., et al. (2020) Macrophage-Derived Exosomes Attenuate Fibrosis in Airway Epithelial Cells through Delivery of Antifibrotic miR-142-3p. Thorax, 75, 870-881. [Google Scholar] [CrossRef] [PubMed]
[20] Zhao, Y., Du, L., Sun, J., Wang, X., Cong, Z., Chen, S., et al. (2023) Exosomal miR-218 Derived from Mesenchymal Stem Cells Inhibits Endothelial-to-Mesenchymal Transition by Epigenetically Modulating of BMP2 in Pulmonary Fibrosis. Cell Biology and Toxicology, 39, 2919-2936. [Google Scholar] [CrossRef] [PubMed]
[21] Zhou, Y., Gao, Y., Zhang, W., Chen, Y., Jin, M. and Yang, Z. (2021) Exosomes Derived from Induced Pluripotent Stem Cells Suppresses M2-Type Macrophages during Pulmonary Fibrosis via miR-302a-3p/TET1 Axis. International Immunopharmacology, 99, Article ID: 108075. [Google Scholar] [CrossRef] [PubMed]
[22] Lu, H., Liu, X., Zhang, M., Bera, H., Xu, W., Jiang, H., et al. (2024) Pulmonary Fibroblast-Specific Delivery of siRNA Exploiting Exosomes-Based Nanoscaffolds for IPF Treatment. Asian Journal of Pharmaceutical Sciences, 19, Article ID: 100929. [Google Scholar] [CrossRef] [PubMed]